Subgroup analyses of adjusted ORs indicated that a per 1 mg/L increase in CRP was significantly associated with a higher risk of sarcopenia in NDD‐CKD patients (adjusted OR = 2.75; 95% CI: 1.71–4.44; p < 0.001; Figure 5) and HD patients (crude OR = 1.21; 95% CI: 1.05–1.39; p = 0.011; adjusted OR = 0.45; 95% CI: 0.05–4.08; p = 0.476; Figure 5). This evidence concerns the gene CRP and chronic kidney disease.